Regulators issue approvable letter for Seasonique

Barr Pharmaceuticals says the FDA has issued an "approvable" letter for Duramed's Seasonique and is preparing to provide additional information on the oral contraceptive requested by the agency. "We are pleased that the agency has determined that our Seasonique extended-cycle oral contraceptive product is approvable for the prevention of pregnancy, which was the clinical endpoint of our original study," said Bruce L. Downey, Barr's chairman and CEO. "We intend to seek a meeting with the Agency within the next 30 days to discuss our on-going studies of Seasonique and how they might satisfy FDA's request for additional information."

- read this press release for more information

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.